Title : Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

Pub. Date : 2015 Oct 21

PMID : 26490659






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 This study aimed to evaluate the predictive significance of the serum p53 antibody status in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy. Oxaliplatin tumor protein p53 Homo sapiens